EFPIA Welcomes EU/Vietnam Trade Deal That ‘Goes Beyond TRIPS’
This article was originally published in PharmAsia News
The R&D-based pharmaceutical industry in Europe has welcomed the agreement between the EU and Vietnam on a free trade deal that will remove almost all tariffs on goods traded between the two economies while implementing strong intellectual property protections for pharmaceuticals.
You may also be interested in...
Coronavirus Update: Setback With Hydroxychloroquine, Slowdown In UK ADR Reports, But Novel Drugs Begin Trials
In addition to our daily in-depth coverage of key events relating to the coronavirus, we’re bringing you a periodic round-up of other pandemic developments. This edition covers events at the national, European and global level.
Participants in a recent webinar looked at how the coronavirus is changing the way we look at clinical trials and whether new EU COVID-19 guidance might hold lessons for future approaches to study design.
There is much talk around the importance of clinical trials in finding new treatments and vaccines for COVID-19 patients, but observational studies in clinical practice also have a vital role to play, including the impact on pregnant women.